Recursion Pharmaceuticals (RXRX) investor relations material

Company evolution and platform integration

• Recent merger combined expertise in AI-driven chemistry and biology, creating a unified platform for drug discovery and development.

• Integrated phenomic, transcriptomic, and real-world patient data systems to identify new biological targets and optimize drug candidates.

• Developed ClinTech business to enhance patient selection and clinical trial optimization, increasing enrollment rates by 30%-60%.

• Differentiation achieved by integrating proprietary data, validation cases, and platform capabilities.

Portfolio strategy and partnerships

• Consolidated internal pipeline from 10 to 5 clinical agents, focusing on high-impact, differentiated programs.

• Maintains about 15 discovery programs, balancing internal and partner-driven projects.

• Major partnerships with Sanofi and Roche, achieving significant milestones and upfront payments, including $150M from Roche and $60M in milestones.

• Partnership programs structured for capital efficiency, with milestone payments and royalties providing strong economics.

• Risk and diversification managed by balancing internal and partner pipelines.

Clinical pipeline and upcoming milestones

• Positive proof-of-concept for lead orphan drug program in FAP, showing near 50% response rates and durable effects.

• Clarifying pivotal trial pathway with FDA, with additional data and trial initiation expected in the first half of next year.

• Four other clinical programs to deliver data readouts by mid-next year, each addressing previously unsolved challenges.

• Upcoming clinical data will validate platform's ability to overcome biological and chemical obstacles.